Short answer
Pacira BioSciences, Inc. (PCRX) filed its Q1 2026 10-Q quarterly report on Apr 30, 2026 for the quarter ended Mar 31, 2026. Quarterly revenue was $177M (up 5.0% year over year) with net income of $3M.
Q1 2026 key financials · XBRL
- Revenue
- $177M
- +5.0% YoY
- Net income
- $3M
- −39.4% YoY
- Operating margin
- 3.9%
- EPS (diluted)
- $0.07
- −30.0% YoY
Source: XBRL data from the Pacira BioSciences, Inc. (PCRX) Q1 2026 10-Q on SEC EDGAR. USD.
Pacira BioSciences, Inc. Q1 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Financing cash use $3.0M in Q1 2025, including $2.8M voluntary term-loan prepayment
- Revolving facility balance $86.0M after $5.0M repayment in Q1 2026
- Cash sufficient to fund operations, capital expenditures, and debt payments through next 12 months
- Potential milestone payments up to $372.3M tied to regulatory and commercial milestones
- Headwinds including inflation, tariffs, supply constraints, capital-market access, and commercialization costs
Risk Factors
- No material risk-factor changes from the 2025 Annual Report
- Carried-forward risks may materially affect business, financial condition, cash flows, or future results
- Regulatory and compliance exposure includes requirements affecting share repurchases
- Capital-allocation risk: $99,998,365 remaining under the repurchase authorization
- Market risk: repurchase timing depends on stock price and market conditions
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Pacira BioSciences, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.